Emma I. Andersson

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.

Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.

Journal: Scientific reports

Published: March 21, 2025

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.

Journal: Acta oncologica (Stockholm, Sweden)

Published: October 29, 2022

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.

Journal: Biomarker research

Published: September 05, 2020

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.

Journal: PloS one

Published: June 18, 2020

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL.

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL.

Journal: Cancers

Published: February 18, 2020

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.

Journal: Haematologica

Published: January 24, 2019

Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

Journal: Cancer research

Published: November 22, 2017

A guilt-by-association mutation network in LGL leukemia.

A guilt-by-association mutation network in LGL leukemia.

Journal: Oncotarget

Published: September 13, 2017

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Journal: Scientific reports

Published: June 19, 2017

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Journal: Nature communications

Published: June 15, 2017

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Journal: Leukemia

Published: May 26, 2017

Drug-perturbation-based stratification of blood cancer.

Drug-perturbation-based stratification of blood cancer.

Journal: The Journal of clinical investigation

Published: March 08, 2017

Showing 1-12 of 26

Last Updated: 09/26/2026